Upon joining the study, the participant must have signed and dated an informed consent form.

The participant should be an adult aged between 18 and 75 years, with specific age requirements for participants from South Korea and Thailand.

The participant’s body mass index (BMI) should be between 18 and 39.9 kg/m².

The participant must have a diagnosis of atopic dermatitis (AtD) for at least one year.

The participant should have an Investigator’s Global Assessment (IGA) score of 3 or higher at both the screening and baseline visits.

The participant should have atopic dermatitis affecting at least 10% of their body surface area at both the screening and baseline visits.

The participant should have an Eczema Area and Severity Index (EASI) score of 16 or higher at both the screening and baseline visits.

The participant should have a baseline pruritus numerical rating scale average score for maximum itch intensity of at least 3, based on the average of daily scores reported during the 7 days prior to randomization.

Participants who have previously used biologic therapies for atopic dermatitis, such as dupilumab, tralokinumab, or lebrikizumab, must meet specific conditions related to their response or tolerance to these treatments.

Biologic naive participants must have a recent history of inadequate response to a stable regimen of prescription topical medication or intolerance to such medications.

Participants should apply a stable dose of non-medicated topical moisturizer at least twice daily for at least 7 days prior to the baseline visit.

The study involves the administration of GSK1070806, a humanised IgG1 kappa monoclonal antibody against interleukin 18, via subcutaneous injection.

The treatment is compared to a placebo, which is a locally sourced 0.9% sodium chloride injection.

The primary endpoint of the study is the percent change from baseline in the Eczema Area and Severity Index (EASI) at week 16.